3Vuitton DA. The ambiguous role of immunity in echinococco protection of the host or of the parasite[J]. Acta Trop,2003,85 (2) ~ 119-132.
4Wilson JF, Rausch RL, McMahon BJ, et al. Parasitocidal effect of chemotherapy in alveolar hydatid disease: review of ex- perience with mebendazole and albendazole in Alaskan Eskimos [J]. Clin Infect Dis,1992,15(2):234-249.
5Yoshioka K, Kakumu S, Arao M, et al. Immunohistochemical studies of intrahepatic tumor necrosis factor alpha in chronic liv er disease[J]. J Chin Pathol, 1990,43 (4) : 298-302.
6MakbV, Czflcz J, Weiszhir Z, tion pattern of human umbilical IL-I, TNF-x, and LPS[J] 962-970. et al. Proinflammatory activa- vein endothelial cells induced by Cytometry A, 2010, 77 (10).
7Kern P. Medical treatment of echinococcosis under the guidance of good clinical practice(GCP/ICH) [J]. Parasitol Int, 2006, 55 :$273-$282.
8Reuter S, Buck A, Grebe O, et al. Salvage treatment with am- photericin B in progressive human alveolar echinococcosis[J] Antimicrob Agents Chemother, 2003,47 (11) : 3586-3591.
9Reuter S, Merkle M, Brehm K, et al. Effect of Amphotericin B on larval growth of Echinococcus multilocularis[J]. Antimicroh Agents Chemother, 2003,47 : 620-625.
10Elissondo MC, Ceballos L, Alvarez L, et al. Flubendazole and ivermectin in vitro combination therapy produces a marked effect on Echinococcus granulosus protoscoleces and metaces- todes[J]. Parasitol Res, 2009,105:835-842.
